PDS Biotech provides a proprietary platform that delivers interleukin‑12 (IL‑12) directly into the interior of solid tumors, reprogramming the immunosuppressive microenvironment and enabling robust infiltration of tumor‑killing T cells.
Funding
$11M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many solid tumors create an immunosuppressive microenvironment that blocks effective T‑cell infiltration and activity, making it difficult to achieve durable anti‑cancer immune responses with existing immunotherapies.
Solution
PDS Biotech has developed a proprietary platform that delivers interleukin‑12 (IL‑12) directly into the tumor interior. Local IL‑12 release reprograms the tumor microenvironment, reducing immunosuppressive signals and enhancing the recruitment and activation of tumor‑infiltrating T cells. By combining microenvironment modulation with a targeted T‑cell attack, the approach aims to overcome tumor immune evasion and generate a potent, localized anti‑cancer response. The technology is designed for integration into cell‑based or gene‑therapy programs to improve efficacy without systemic toxicity.
Target Audience
Primary customers are oncology biotech and pharmaceutical companies developing T‑cell‑based immunotherapies, as well as academic and clinical research groups focused on solid‑tumor immunology.
Features
- Targeted delivery system that transports IL‑12 into the tumor’s inner environment
- Localized cytokine release to suppress tumor immune‑protective mechanisms
- Induction of high‑density, functional tumor‑infiltrating T cells for focused tumor attack
- Platform (Versamune®) engineered to coordinate cytokine delivery with T‑cell activation
- Designed to minimize systemic exposure and associated side effects